Journals / Turkish Journal of Gastroenterology / 2004 / Cilt: 15 - Sayı: 1

Hepatit C genotip 1b ile Türk hastaların interferon tedavisine verdiği cevap NS5A geninin ISDR bölgesindeki mutasyonlarla ilişkili değildir

The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection

Pages
21–26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the majority of the patients, it seems that amino acid sequences in this region are well conserved.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A significant association between variations in amino acid sequences resides between 2209-2248 nucleotides of HCV non-structural 5A (NS5A) gene, and response to interferon treatment has been proposed.
📊
Key Findings & Data:The aim of this study was to determine whether the amino acid sequence changes in ISDR could be correlated to response to alpha interferon treatment in Turkish patients infected with HCV genotypes 1b and 1a.
💡
Conclusion & Impact:In the majority of the patients, it seems that amino acid sequences in this region are well conserved.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Genler · İnterferon-alfa · Mutasyon

Abstract

A significant association between variations in amino acid sequences resides between 2209-2248 nucleotides of HCV non-structural 5A (NS5A) gene, and response to interferon treatment has been proposed. The aim of this study was to determine whether the amino acid sequence changes in ISDR could be correlated to response to alpha interferon treatment in Turkish patients infected with HCV genotypes 1b and 1a. Methods: Thirty-nine patients with chronic C virus infection (35 and 4 patients with genotype 1b and 1a, respectively), receiving 3x3-5 MU of interferon $\alpha$-2b for six months were included in the study. Following PCR amplification of the region from pre-treatment serum samples, the products were directly sequenced. The amino acid sequence of NS5A was compared with the published sequence for HCV-J (AA 2209-2248). Mutant type was defined as three or more amino acid mutations, and intermediate type as 1-3 amino acids in this region. Otherwise, they were defined as the wild type (no amino acid mutations). HCV RNA serum viremia levels were analyzed by branched DNA assay. Results: Eighteen patients were responders (R; 46%), whereas 21 patients were non-responders (NR; 54%). Amino acid changes in both R and NR groups did not show significant difference. Intermediate or wild type strains were detected in both groups. Conclusions: In this study, we could not determine a significant association between number of amino acid changes in NS5A2209-2248 and response to interferon treatment. In the majority of the patients, it seems that amino acid sequences in this region are well conserved.

Özet

HCV-NS5A geni (2209-2248 nt) üzerindeki aa değişimleri ile interferon tedavisine yanıt arasında bir ilişki olduğu rapor edilmiştir. Bu çalışmamızın amacı HCV genotip 1b ile enfekte Türk hastalarının IFN tedavisine verdikleri yanıtla ISDR bölgesindeki aa değişimleri arasında bir ilişki olup olmadığını incelemektedir. Yöntem: Çalışma grubumuzda 6 ay boyunca 3x3-5 MIU interferon $\alpha$ 2b tedavisi alan 39 kronik C hastası (35:1b, 4:1a) bulunmaktadır. Tedavi öncesi serum örneklerinden yapılan PZR amplifikasyonları sonrası sekanslar gerçekleştirildi. Mutant tiplerde 4 aa’dan faza mutasyonlar tespit edilirken, orta tiplerde 1-3 aa mutasyon bulunmaktadır. Yaban tipte ise hiçbir aa değişimi yoktur. HCV-RNA serum virüs düzeyleri bDNA yöntemi ile analiz edildi. Bulgular: Onsekiz hasta tedaviye yanıt verirken (%46), 21 hastada yanıt alınamamıştır(%54). Aminoasit değişimleri bu iki hasta grubunda önemli bir farklılık göstermemiştir. İki grupta da orta ve yaban tip mutasyon türleri gözlenmiştir. Sonuç: Bu çalışmada IFN’a cevap ile NS5A2209-2248 bögesindeki aa değişimleri arasında bir ilişki bulunamamıştır. Hastaların büyük bir kısmında aa dizileri korunmuşluk göstermektedir.

🔖

Cite This Article

ASLAN, N., BOZDAYI, A. M., ÇETİNKAYA, H., SARIOĞLU, M., TÜRKAY, C., BOZKAYA, H., KARAYALÇIN, S., YURDAYDIN, C., UZUNALİMOĞLU, Ö. (2004). Hepatit C genotip 1b ile Türk hastaların interferon tedavisine verdiği cevap NS5A geninin ISDR bölgesindeki mutasyonlarla ilişkili değildir. Turkish Journal of Gastroenterology, Cilt: 15 - Sayı: 1, 21–26. https://ajindex.com/articles/410904

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dienstang JL. Non-A, non-B hepatitis. I. Recognition, epi demiology and clinical features. Gastroenterology 1983; 85: 439-62
  2. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Therapy Group. N Engl J Med 1989; 321: 1501-6
  3. Di Bisceqlie AM, Martin P, Kassianides C, et al. Recombi nant interferon alfa therapy for chronic hepatitis C. A ran domized, double blind, placebo-controlled trial. N Eng J Med 1989; 321: 1506-10
  4. Chemello L, Cavalletto L, Donada C, et al. Efficacy of a se cond cycle of interferon therapy in patients with chronic he patitis C. Gastroenterology 1997; 113: 1654-9
  5. Brower JT, Nevens F, Kleter G, et al. Efficacy of interferon dose and factors predictive of sustained response in chronic hepatitis C: final results of a Benelux multicenter study in 350 patients (Abstract). J Hepatol 1995; SI: 85
  6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 we eks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Inter national Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 31: 1426-32
  7. Camps J, Crisostomo S, Garcia-Granero M, et al. Predicti on of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714-7
  8. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3
  9. Lam NP, De Guzman LJ, Pitrak D, Layden TJ. Clinical and histologic predictors of response to interferon-alfa in patients with chronic hepatitis C viral infection. Dig Dis Sci 1994; 39: 2660-4
  10. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full length sequences of interferon-sensitive and resistant he patitis C virus I b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-30
  11. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection. N Engl J Med 1996; 334: 77-81
  12. Sen GC, Ransohoff RM. Interferon induced antiviral acti ons and their regulation. Adv Virus Res 1993; 42: 57-102
  13. Hershey JWB. Translational control in mammalian cells. Anu Rev Biochem 1991; 60: 717-55
  14. Merrick WC, Hershey JWB. Translational Control. In